DK156565C - Analogifremgangsmaade til fremstilling af substituerede morpholinderivater - Google Patents

Analogifremgangsmaade til fremstilling af substituerede morpholinderivater

Info

Publication number
DK156565C
DK156565C DK022679A DK22679A DK156565C DK 156565 C DK156565 C DK 156565C DK 022679 A DK022679 A DK 022679A DK 22679 A DK22679 A DK 22679A DK 156565 C DK156565 C DK 156565C
Authority
DK
Denmark
Prior art keywords
preparation
morpholine derivatives
substituted morpholine
analogy procedure
analogy
Prior art date
Application number
DK022679A
Other languages
Danish (da)
English (en)
Other versions
DK22679A (da
DK156565B (da
Inventor
Piero Melloni
Arturo Della Torre
Giovani Claudio Carniel
Alessandro Rossi
Original Assignee
Erba Carlo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT1945078A external-priority patent/IT1111676B/it
Priority claimed from IT1944978A external-priority patent/IT1093255B/it
Priority claimed from IT3053378A external-priority patent/IT1160301B/it
Priority claimed from IT30535/78A external-priority patent/IT1101724B/it
Priority claimed from IT3053478A external-priority patent/IT1160302B/it
Application filed by Erba Carlo Spa filed Critical Erba Carlo Spa
Publication of DK22679A publication Critical patent/DK22679A/da
Publication of DK156565B publication Critical patent/DK156565B/da
Application granted granted Critical
Publication of DK156565C publication Critical patent/DK156565C/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/32Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups bound to acyclic carbon atoms and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/37Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01Preparation of ethers
    • C07C41/16Preparation of ethers by reaction of esters of mineral or organic acids with hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/41Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by hydrogenolysis or reduction of carboxylic groups or functional derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/58Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/321,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/321,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C07D265/33Two oxygen atoms, in positions 3 and 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/12Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/24Ethers with hydroxy compounds containing no oxirane rings with polyhydroxy compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK022679A 1978-01-20 1979-01-18 Analogifremgangsmaade til fremstilling af substituerede morpholinderivater DK156565C (da)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
IT1945078A IT1111676B (it) 1978-01-20 1978-01-20 Derivati della 2-fenossimetil-morfolina
IT1944978 1978-01-20
IT1944978A IT1093255B (it) 1978-01-20 1978-01-20 Derivati fenossialcanolaminici
IT1945078 1978-01-20
IT3053378A IT1160301B (it) 1978-12-05 1978-12-05 Derivati fenossialcanolaminici
IT3053578 1978-12-05
IT3053478 1978-12-05
IT3053378 1978-12-05
IT30535/78A IT1101724B (it) 1978-12-05 1978-12-05 Derivati morfolinici e fenossiprofanolaminici e procedimento per la loro preparazione
IT3053478A IT1160302B (it) 1978-12-05 1978-12-05 Derivati della 2-fenossimentil-morfolina

Publications (3)

Publication Number Publication Date
DK22679A DK22679A (da) 1979-07-21
DK156565B DK156565B (da) 1989-09-11
DK156565C true DK156565C (da) 1990-02-05

Family

ID=27517788

Family Applications (1)

Application Number Title Priority Date Filing Date
DK022679A DK156565C (da) 1978-01-20 1979-01-18 Analogifremgangsmaade til fremstilling af substituerede morpholinderivater

Country Status (24)

Country Link
US (2) US4229449A (fr)
JP (1) JPS54148739A (fr)
AT (1) AT371813B (fr)
AU (1) AU525954B2 (fr)
BG (1) BG61056B2 (fr)
CA (1) CA1128942A (fr)
CH (1) CH650245A5 (fr)
CS (1) CS413391A3 (fr)
CY (1) CY1172A (fr)
DE (2) DE2901032C2 (fr)
DK (1) DK156565C (fr)
FI (1) FI71135C (fr)
FR (2) FR2442839A1 (fr)
GB (1) GB2014981B (fr)
HK (1) HK5783A (fr)
IE (1) IE47727B1 (fr)
IL (1) IL56369A (fr)
KE (1) KE3243A (fr)
MY (1) MY8400018A (fr)
NO (1) NO146953C (fr)
NZ (1) NZ189418A (fr)
SE (1) SE446727B (fr)
SI (1) SI7910096A8 (fr)
YU (1) YU42094B (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226523A (en) * 1978-11-17 1980-10-07 Energy Conversion Devices, Inc. Imaging device
GB2162517B (en) * 1984-08-01 1988-04-27 Erba Farmitalia Process for the preparation of 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB8419683D0 (en) * 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
DE3546929B4 (de) * 1984-08-02 2006-02-09 Pharmacia Italia S.P.A. 1,2-substituierte Derivate von 3-Phenoxy-3-Phenylpropan
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
GB8823405D0 (en) * 1988-10-05 1988-11-09 Erba Carlo Spa Aryloxy-arythio-heteraryloxy-heteroarylthio-alkenylene derivatives of amines
FR2754709B1 (fr) 1996-10-23 1999-03-05 Sanofi Sa Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition
AU9214498A (en) * 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
EP1069900B1 (fr) 1998-04-09 2005-08-10 Pharmacia & Upjohn Company LLC Nouveaux traitements avec "reboxetine" pour troubles nerveux
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
IT1305322B1 (it) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
CN1249038C (zh) * 1998-12-29 2006-04-05 法玛西雅厄普约翰美国公司 芳基醚的制备方法
AU2005220235B2 (en) * 1999-07-01 2007-05-10 Pharmacia & Upjohn Company Selective norepinephrine reuptake inhibitors and methods of using the same
DK1459751T3 (da) * 1999-07-01 2005-12-19 Pharmacia & Upjohn Co Llc (S,S)reboxetin til behandling af migrænehovedpine
PT1459751E (pt) * 1999-07-01 2005-11-30 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para tratar as enxaquecas
CO5210862A1 (es) 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
US20040048860A1 (en) * 2000-10-31 2004-03-11 Jes Olesen Use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
US20040034106A1 (en) * 2001-11-06 2004-02-19 Read Holly Ann Treatment of anxiety disorders
ES2287338T3 (es) * 2001-11-30 2007-12-16 Eli Lilly And Company Uso de inhibidores de recaptacion de norepinefrina para el tratamiento de trastornos de tics.
MXPA04009352A (es) * 2002-04-18 2005-01-25 Pharmacia Corp Terapia de combinacion para el tratamiento de la enfermedad de parkinson con inhibidores de ciclooxigenasa-2 (cox2).
AU2003261185A1 (en) * 2002-08-14 2004-03-03 Pharmacia & Upjohn Company Llc Use of reboxetine for the treatment of hot flashes
US20040229849A1 (en) * 2002-09-24 2004-11-18 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
WO2004043904A1 (fr) * 2002-11-05 2004-05-27 Eli Lilly And Company Composes pharmaceutiques
TWI316511B (en) 2002-11-26 2009-11-01 Smithkline Beecham Corp Calcilytic compounds
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
BRPI0409492A (pt) * 2003-04-18 2006-05-02 Pharmacia & Up John Company Ll terapias de combinação
WO2005011583A2 (fr) * 2003-07-28 2005-02-10 Leslie Joe Dunaway Traitement de la rhinite allergique et de l'asthme
RU2006107534A (ru) * 2003-09-12 2007-09-20 Уорнер-Ламберт Компани Ллс (Us) Комбинация, включающая альфа-2-дельта-лиганд анд и ssri и/или snri, для лечения депрессии и тревожного расстройства
RU2320369C2 (ru) 2003-09-12 2008-03-27 Пфайзер Инк. Комбинации, содержащие альфа-2-дельта лиганды и ингибиторы обратного захвата серотонина/норадреналина
US7402698B2 (en) * 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7419980B2 (en) * 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7491723B2 (en) * 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7524846B2 (en) * 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7531543B2 (en) * 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
WO2005082869A1 (fr) * 2004-02-20 2005-09-09 Pharmacia & Upjohn Company Llc Procede pour la preparation d'ethers aryle
CA2556063A1 (fr) * 2004-02-20 2005-09-09 Pharmacia & Upjohn Company Llc Procede pour la preparation d'ethers aryle
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) * 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
WO2005105763A1 (fr) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Composes de morpholine substitues permettant de traiter des troubles du systeme nerveux central
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
CA2604916A1 (fr) 2005-04-22 2006-11-02 Wyeth Derives de dihydrobenzofurane et utilisations associees
MX2007013021A (es) * 2005-04-22 2008-01-11 Wyeth Corp Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
EP2317316A3 (fr) 2005-07-08 2011-06-15 Braincells, Inc. Procédés permettant d'identifier l'agent et les conditions qui modulent la neurogénèse
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス,インコーポレイティド Pde阻害による神経新生の調節
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
BRPI0709159A2 (pt) * 2006-03-24 2011-06-28 Wyeth Corp combinações terapêuticas para o tratamento de depressão
US20080020387A1 (en) * 2006-03-31 2008-01-24 Lawrence Donald G Biomarker-optimized adhd treatment
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド 5ht受容体介在性の神経新生
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008019431A1 (fr) * 2006-08-14 2008-02-21 Brc Operations Pty Limited Procédé et compositions pour réguler simultanément la mémoire et l'humeur
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2663984C (fr) 2006-10-18 2012-02-21 Pfizer Products Inc. Composes d'uree de bisaryle ether
WO2008122019A1 (fr) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Amélioration de la tolérabilité de la mirtazapine et de la réboxétine par leur utilisation en combinaison
CN101613347B (zh) * 2008-06-23 2012-07-04 中国人民解放军军事医学科学院毒物药物研究所 胺类化合物及其医药用途
TWI438190B (zh) * 2008-07-24 2014-05-21 Theravance Inc 3-(苯氧基苯基甲基)吡咯啶化合物
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
DK2358675T3 (da) 2008-11-14 2013-01-14 Theravance Inc 4-[2-(2-Fluorphenoxymethyl)phenyl]piperidinforbindelser
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
US20100267743A1 (en) * 2009-04-15 2010-10-21 Stangeland Eric L 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
CA2767372A1 (fr) * 2009-07-13 2011-01-20 Theravance, Inc. Composes 3-phenoxymethylpyrrolidines
ES2495366T3 (es) 2009-07-21 2014-09-17 Theravance, Inc. Compuestos de 3-fenoximetilpirrolidina
EP2523945A1 (fr) 2010-01-11 2012-11-21 Theravance, Inc. Composés de type 1-(2-phénoxyméthylphényl)pipérazine comme inhibiteurs du recaptage de la sérotonine et de la norépinéphrine
WO2011119461A1 (fr) * 2010-03-22 2011-09-29 Theravance, Inc. Composés de 1-(2-phénoxyméthylhétéroaryl)pipéridine et pipérazine
CA2811641A1 (fr) 2010-10-11 2012-04-19 Theravance, Inc. Inhibiteurs de la reabsorption de serotonine
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138405A (en) * 1966-12-28 1969-01-01 Ici Ltd Morpholine derivatives
BE759013R (fr) * 1969-11-17 1971-05-17 Ici Ltd Derives de la
GB1382526A (en) * 1972-08-11 1975-02-05 Ici Ltd Morpholine derivatives
GB1412546A (en) * 1973-08-08 1975-11-05 Ici Ltd Morpholine derivatives
GB1427097A (en) * 1973-10-18 1976-03-03 Ici Ltd Optically-active morpholine derivatives
GB1469410A (en) * 1973-12-17 1977-04-06 Christiaens Sa A Benzodioxole derivatives
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1576216A (en) * 1975-01-29 1980-10-01 Yamanouchi Pharma Co Ltd 2-(7-indenyloxymethyl)-morpholine derivatives and process of producing them
CA1064927A (fr) * 1975-01-29 1979-10-23 Yuji Kawashima Procede pour la production de derives de la 2-indenyloxymethymorpholine
CA1085841A (fr) * 1976-05-19 1980-09-16 Jean-Marie Ferland Obtention et emploi d'aryloxypropylamines

Also Published As

Publication number Publication date
SE7900498L (sv) 1979-07-21
US4229449A (en) 1980-10-21
YU9679A (en) 1983-12-31
DE19875005I2 (de) 2002-10-24
CH650245A5 (de) 1985-07-15
FR2442839B1 (fr) 1984-07-27
SE446727B (sv) 1986-10-06
MY8400018A (en) 1984-12-31
DE2901032A1 (de) 1979-08-02
CY1172A (en) 1983-06-10
NZ189418A (en) 1981-03-16
FR2430412A1 (fr) 1980-02-01
IE790107L (en) 1979-07-20
KE3243A (en) 1982-12-03
SI7910096A8 (sl) 1996-10-31
CA1128942A (fr) 1982-08-03
GB2014981B (en) 1982-08-11
FI71135B (fi) 1986-08-14
IE47727B1 (en) 1984-05-30
FI790177A (fi) 1979-07-21
FI71135C (fi) 1986-11-24
HK5783A (en) 1983-02-08
JPS54148739A (en) 1979-11-21
YU42094B (en) 1988-04-30
NO146953B (no) 1982-09-27
FR2442839A1 (fr) 1980-06-27
IL56369A (en) 1984-05-31
GB2014981A (en) 1979-09-05
BG61056B2 (bg) 1996-09-30
AU525954B2 (en) 1982-12-09
NO790205L (no) 1979-07-23
IL56369A0 (en) 1979-03-12
AU4332779A (en) 1979-07-26
NO146953C (no) 1983-01-05
ATA40679A (de) 1982-12-15
AT371813B (de) 1983-08-10
FR2430412B1 (fr) 1987-06-26
DK22679A (da) 1979-07-21
JPS6331455B2 (fr) 1988-06-23
DK156565B (da) 1989-09-11
CS413391A3 (en) 1992-05-13
US4271160A (en) 1981-06-02
DE2901032C2 (de) 1996-05-30

Similar Documents

Publication Publication Date Title
DK156565C (da) Analogifremgangsmaade til fremstilling af substituerede morpholinderivater
DK158225C (da) Analogifremgangsmaade til fremstilling af carbostyrilderivater
DK158788C (da) Analogifremgangsmaade til fremstilling af tetrazolylalkoxycarbostyrilderivater
DK46079A (da) Fremgangsmaade til fremstilling af alkylendiaminderivater
DK266479A (da) Fremgangsmaade til fremstilling af 3-aminopropoxyarylderivater
DK303079A (da) Fremgangsmaade til fremstilling af imidazolderivater
DK146962C (da) Analogifremgangsmaade til fremstilling af indolizinderivater
DK155669C (da) Analogifremgangsmaade til fremstilling af pleuromutilinderivater
DK159269C (da) Analogifremgangsmaade til fremstilling af svovlholdige indanylderivater
DK310779A (da) Fremgangsmaade til fremstilling af pyrimidinonderivater
DK158984C (da) Analogifremgangsmaade til fremstilling af carbostyrilderivater
DK149773C (da) Analogifremgangsmaade til fremstilling af 3-quinolincarboxylsyrederivater
DK161026C (da) Analogifremgangsmaade til fremstilling af antigenderivater
DK145698C (da) Analogifremgangsmaade til fremstilling af 2-alkoxyadeninderivater
DK186179A (da) Fremgangsmaade til fremstilling af carbapenemderivater
DK156643C (da) Analogifremgangsmaade til fremstilling af naphthalensulfonamidderivater
DK148259C (da) Fremgangsmaade til fremstilling af lysergolderivater
DK147145C (da) Analogifremgangsmaade til fremstilling af chlorambucilderivater
DK415379A (da) Fremgangsmaade til fremstilling af chromanolderivater
DK321479A (da) Fremgangsmaade til fremstilling af 1-phenylpiperazinderivater
DK154970C (da) Analogifremgangsmaade til fremstilling af carbostyrilderivater
DK154434C (da) Analogifremgangsmaade til fremstilling af tripeptidderivater
DK149748C (da) Analogifremgangsmaade til fremstilling af n-phenethylacetamidforbindelser
DK186279A (da) Fremgangsmaade til fremstilling af alkylcarbapenemderivater
DK160281C (da) Fremgangsmaade til fremstilling af steroid-s-thioesterderivater

Legal Events

Date Code Title Description
CTFF Application for supplementary protection certificate (spc) filed

Free format text: CA 1998 00005, 980204

PUP Patent expired